

Attorney Document No. MBP-005XX
Filed: Herewith
Group Art Unit:

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter which would expedite allowance of the present application.

Respectfully submitted,

KERSTIN KRIEGELSTEIN

By: 

Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant
WEINGARTEN, SCHURGIN, GAGNEBIN
& HAYES LLP
Ten Post Office Square
Boston, MA 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

Date: 3-2-1

CLG/jde/243729

RECEIVED
MAR 2 1991
FBI - BOSTON

MARKED-UP VERSION OF AMENDED CLAIMS TO IPER

1 3. Use according to claim 1 ~~or 2~~, wherein said disorder is a
2 peripheral and/or CNS-disorder.

1 7. The pharmaceutical composition according to claim 5 ~~or 6~~,
2 wherein said compound is an antibody directed to TGF- β or a
3 compound having the binding site of a TGF- β receptor.

1 8. The pharmaceutical composition according to ~~anyone of~~
2 ~~claims 5 to 7~~ claim 5, wherein said second compound is selected
3 from the group consisting of urokinase and tissue plasminogen
4 activator.